In Segment C, members will receive ABBV-744 and oral navitoclax. In Section D, contributors will obtain ABBV-744 and ruxolitinib. Individuals will get treatment until disorder progression or the individuals are unable to tolerate the study drugs. For all movement cytometry experiments, 10,000 cel